Summaries & Associations of Study Results
TR-499 Indium Phosphide
Target Organs and Levels of Evidence
NTP Technical Report Number 499
Produced from Chemtrack Database 12/24/03
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| INDIUM PHOSPHIDE 22398-80-7 |
05/18/00 | USED IN ELECTRONICS INDUSTRY; IN SEMICONDUCTOR DEVICES, INJECTOR LASERS, AND SOLAR CELLS. PROPOSED TO REPLACE SILICON IN COMPUTER MICROCHIPS. | Inhalation R&M: 0, 0.03, 0.1, OR 0.3 MG/M3 | Battelle Northwest Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: CLEAR EVIDENCE | LUNG: ALVEOLAR/BRONCHIOLAR ADEMONA 6/50 13/50 27/50 30/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 10/50 8/50 16/50; COMBINED 7/50 22/50 30/50 35/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 4/50 | |||
| ADRENAL GLAND: (MEDULLA) BENIGN PHEOCHROMOCYTOMA 10/50 22/50 16/49 23/50 BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 10/50 26/50 18/49 24/50 | ||||
| MAY HAVE BEEN RELATED: | HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA 16/50 23/50 29/50 25/50 | |||
| SKIN: FIBROMA 1/50 4/50 7/50 3/50; FIBROMA OR FIBROSARCOMA 2/50 4/50 8/50 4/50 | ||||
| NON-NEOPLASTIC LESIONS: | LUNG: ATYPICAL HYPERPLASIA; CHRONIC ACTIVE INFLAMMATION; ALVEOLAR EPITHELIUM METAPLASIA; ALVEOLUS PROTEINOSIS; INTERSTITIUM FIBROSIS; ALVEOLAR EPITHELIUM HYPERPLASIA | |||
| FR: CLEAR EVIDENCE | LUNG: ALVEOLAR/BRONCHIOLAR ADEMONA 0/50 7/50 5/50 19/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 3/50 1/50 11/50; COMBINED 1/50 10/50 6/50 26/50 | |||
| ADRENAL GLAND: (MEDULLA) BENIGN PHEOCHROMOCYTOMA 2/50 6/48 2/50 9/49 | ||||
| MAY HAVE BEEN RELATED: | HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA 14/50 21/50 14/50 24/50 | |||
| MAMMARY GLAND: CARCINOMA 0/50 8/50 3/50 2/50 | ||||
| NON-NEOPLASTIC LESIONS: | LUNG: ATYPICAL HYPERPLASIA; CHRONIC ACTIVE INFLAMMATION; ALVEOLAR EPITHELIUM METAPLASIA; ALVEOLUS PROTEINOSIS; INTERSTITIUM FIBROSIS; ALVEOLAR EPITHELIUM HYPERPLASIA; SQUAMOUS CYST | |||
| ADRENAL GLAND: (MEDULLA) HYPERPLASIA | ||||
| MM: CLEAR EVIDENCE | LUNG: ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 15/50 22/50 13/50 | |||
| LIVER: ADENOMA 17/50 24/50 23/50 32/50; CARCINOMA 11/50 22/50 23/50 16/50; COMBINED 26/50 40/50 37/50 39/50 | ||||
| MAY HAVE BEEN RELATED: | INTESTINES: CARCINOMA 0/50 1/50 5/50 3/50; ADEMONA OR CARCINOMA 1/50 2/50 6/50 3/50 | |||
| NON-NEOPLASTIC LESIONS: | LUNG: CHRONIC ACTIVE INFLAMMATION; ALVEOLUS PROTEINOSIS; SEROSA FIBROSIS; PLEURA MESOTHELIUM HYPERPLASIA | |||
| LIVER: EOSINOPHLILIC FOCUS | ||||
| HEART: (ARTERY) INFLAMMATION | ||||
| FM: CLEAR EVIDENCE | LUNG: ALVEOLAR/BRONCHIOLAR ADEMONA 3/50 6/50 10/50 7/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 6/50 5/50 7/50; COMBINED 4/50 11/50 15/50 14/50 | |||
| LIVER: ADENOMA 12/50 14/50 18/50 14/50; CARCINOMA 6/50 17/50 8/50 10/50; COMBINED 18/50 28/50 24/50 23/50 | ||||
| NON-NEOPLASTIC LESIONS: | LUNG: CHRONIC ACTIVE INFLAMMATION; ALVEOLUS PROTEINOSIS; SEROSA FIBROSIS; PLEURA MESOTHELIUM HYPERPLASIA | |||
| LIVER: EOSINOPHILIC FOCUS | ||||
| HEART: (ARTERY) INFLAMMATION | ||||
Web page last updated on February 10, 2006
